Launched more than a year ago, the RAMSES cohort now includes more than 1,400 patients and 49 centers * open to inclusions across France.

This epidemiological study, carried out by Prof Camille Taillé (Pneumology Department A, Bichat – Claude-Bernard AP-HP hospital), Dr Candice Estellat (Pharmacoepidemiology Center, Pitié Salpêtrière AP-HP hospital), Prof Arnaud Bourdin ( CHU de Montpellier), Prof Cécile Chenivesse (CHU de Lille), Prof Gilles Devouassoux (Hospices Civils de Lyon) and Prof Gilles Garcia (private hospital in Antony), on behalf of the Société de Pneumologie de Langue Française, for the purpose of better understanding the management of severe asthma.

It is made possible thanks to a financing agreement signed between Assistance Publique – Hôpitaux de Paris and the Astrazeneca, GlaxoSmithKLine and Sanofi laboratories over five years as well as support from the French Language Pneumology Society and the Novartis laboratory. On January 5, Boston Scientific joined the RAMSES cohort

In France, more than 60,000 people are affected by severe asthma. This pathology results in persistent respiratory symptoms despite good adherence to treatment with inhaled corticosteroids prescribed at high doses. It is a chronic inflammatory disease of the bronchi whose symptoms can constitute a severe respiratory handicap and be life-threatening during exacerbations. The treatment aims to control asthmatic disease, in order to limit the occurrence of exacerbations, maintain respiratory capacity and reduce daily symptoms (cough, dyspnea, nocturnal awakenings, etc.).

Evaluate strategies for using treatment for severe asthma

The RAMSES project, Recherche sur les AsthMes Sévères, is a cohort, prospective and multicentric observational epidemiological study, initiated by the Asthma and Allergies working group of the French Language Pneumology Society and integrated into the national clinical research research network in severe asthma CRISALIS-F-CRIN. RAMSES should make it possible to assess the modalities of use, the benefits and risks associated with the various real-life treatment strategies in patients suffering from severe asthma.

The main objective of this project is to set up a cohort of adult patients with severe asthma, followed for 5 years, in order to have longitudinal data on the modalities of their management, the benefits and / or the risks associated with the different treatments.

The RAMSES cohort will make it possible to carry out both academic research on severe asthma and to respond, among other things, to the request for post-registration studies (post marketing authorization (MA) required by the Haute Autorité de santé. , for biotherapies.

The coordination and methodology of the RAMSES cohort are provided by the Pharmacoepidemiology Center of AP-HP (CEPHEPI).

The data collected, which will be used for follow-up studies requested by the Haute Autorité de Santé, may also contribute to European or international registers.

* 1,54 participating centres including 49 open centres and 1,446 patients included as of 05/31/2021

About the Antony Private Hospital

The first private establishment in Ile-de-France, the Antony Private Hospital has been a recognized multidisciplinary establishment for over 15 years. Its medical, surgical and obstetric activity is major (More than 3,200 deliveries / More than 85,000 emergency room visits / More than 50,000 stays) and driven by the multidisciplinary and medical dynamism of a community which brings together more than 250 liberal practitioners. Reference center in cancerology, the Private Hospital of Antony is home to the Paris Sud Cancer Institute which itself brings together and coordinates the oncology activities of 3 establishments: the Private Hospital of Antony, the Private Hospital Jacques Cartier and the Amandier Clinic (SSR). Find out more: hpantony.fr